ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents?
Lowering the risk of cardiovascular disease (CVD) involves more than treatment of individual risk factors such as hypertension, diabetes, and chronic kidney disease. In this article, Drs Toto, Rinner, and Ram present an evidence-based approach to reducing CVD risk and suggest that optimal treatment with angiotensin-converting enzyme (ACE) inhibitors should be extended to a larger proportion of at-risk patients and in particular to those not previously considered candidates for use of these agents.
Southwestern Medical School, University of Texas Southwestern Medical Center at Dallas, 75390, USA.
Robert D
RD
Toto
Steven
S
Rinner
C Venkata S
CV
Ram
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control*; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000517:prevention & control; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects*; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D020521:Stroke / Q000188:drug therapy / Q000517:prevention & control; D014481:United States / Q000453:epidemiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents